STRADEFY BIOSCIENCES
Pioneering next-generation Bioadhesive Drug Carriers (BDCs)
OUR MISSION
Stradefy Biosciences is pioneering next-generation bioadhesive drug carriers (BDCs), rationally engineered for cellular bioadhesion, uptake and therapeutic payload release, at levels well beyond seen with antibody drug conjugates (ADCs). Lead candidates, initially targeting unmet needs in the oncology and immunology areas, have demonstrated in vivo proof of efficacy and are advancing to the IND stage.
Based in New Haven, CT, Stradefy was co-founded by Mark Saltzman, Michael Girardi, Yale University and Elm Street Ventures.
Our Research
Improved i.p. drug delivery with bioadhesive nanoparticles
https://www.pnas.org/doi/10.1073/pnas.1523141113
Nonsurgical treatment of skin cancer with local delivery of bioadhesive nanoparticles https://www.pnas.org/doi/10.1073/pnas.2020575118
LEADERSHIP
Mark Saltzman, Ph.D
Jeffrey Goldberg, MS, MBA
Michael Girardi, M.D.
Academic Founder
Goizueta Foundation
Professor of Chemical and Biomedical Engineering
Yale University
Michael Girardi, M.D.
Jeffrey Goldberg, MS, MBA
Michael Girardi, M.D.
Academic Founder
Vice Chair & Evans Prof of Dermatology
Yale School of Medicine
Jeffrey Goldberg, MS, MBA
Jeffrey Goldberg, MS, MBA
Jeffrey Goldberg, MS, MBA
Executive Chair
Brian Dixon, Ph.D.
Jeffrey Goldberg, MS, MBA
Jeffrey Goldberg, MS, MBA
Venture Partner